NLRP3 and atherosclerosis: Neither of the biologics previously listed has received approval for use in clinical practice as an NLRP3 inhibitor alone, despite the NLRP3-IL-1b inflammasome pathway being a potentially valuable therapeutic target for patients with atherosclerosis and other inflammatory conditions [15].